Neurocare Group's iTBS protocol for depression treatment received FDA clearance for the Apollo TMS Therapy System.

Neurocare Group, a mental health innovation leader, received FDA clearance for its Intermittent Theta Burst Stimulation (iTBS) protocol, available across the Apollo TMS Therapy System and other Transcranial Magnetic Stimulation (TMS) systems. The iTBS protocol offers a more efficient, consistent delivery of stimulation power for depression treatment, requiring 3 minutes per session, and covers major depression cases after oral antidepressant failure. The Apollo TMS Therapy system is FDA-cleared and insured-covered.

August 22, 2024
5 Articles

Further Reading